0.5154  -0.011 (-2.03%)		06-30 16:00
Open: 0.561 High: 0.5997 Volume: 25,061,882		Pre. Close: 0.5261 Low: 0.47 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	0.74	1-year :	0.86
Resists	First :	0.63	Second :	0.74
Pivot price	0.54
Supports	First :	0.46	Second :	0.39
MAs	MA(5) :	0.53	MA(20) :	0.56
	MA(100) :	0.72	MA(250) :	0.78
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	34.2	D(3) :	35.7
RSI	RSI(14): 33.1
52-week	High :	2.05	Low :	0.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KTTA ] has closed above bottom band by 24.7%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.58 - 0.58	0.58 - 0.59
Low:	0.51 - 0.51	0.51 - 0.51
Close:	0.52 - 0.53	0.53 - 0.53

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

Tue, 30 Jun 2026
Pasithea reports positive PAS-004 Phase 1 cancer data - grafa.com

Tue, 30 Jun 2026
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion - Investing News Network

Tue, 30 Jun 2026
Pasithea says PAS-004 stayed tolerable in cancer patients as dosing widens - Stock Titan

Mon, 29 Jun 2026
Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTA - TradingView

Tue, 23 Jun 2026
Stonepine Group reports 5.8% stake in Pasithea Therapeutics (KTTA) - Stock Titan

Mon, 22 Jun 2026
Coastlands Capital LP (KTTA) adds 100,000 Pasithea Therapeutics shares in open-market buy - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	33 (M)
Shares Float	17 (M)
Held by Insiders	1.1 (%)
Held by Institutions	63.4 (%)
Shares Short	312 (K)
Shares Short P.Month	297 (K)

EPS	-1.42
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.2
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-31.5 %
Return on Equity (ttm)	-58.3 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.52
Qtrly Earnings Growth	0 %
Operating Cash Flow	-17 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-0.37
PEG Ratio	0
Price to Book value	0.23
Price to Sales	0
Price to Cash Flow	-1.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.